Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4300-4307

  Huang, Fenglei ^a   Koenen Bergmann, Michael ^b   MacGregor, Thomas R ^a   Ring, Arne ^b   Hattox, Susan ^a   Robinson, Patrick ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILR 355; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; EYELID DISEASE; FATIGUE; FEMALE; FLATULENCE; FREQUENT BOWEL MOVEMENT; HEADACHE; HEART PALPITATION; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACULOPAPULAR RASH; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MIGRAINE; MONOTHERAPY; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOLUNTEER; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57049116193     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00363-08     Document Type: Article

References (22)

1. Antinori, A., M. Zaccarelli, A. Cingolani, F. Forbici, M. G. Rizzo, M. P. Trotta, S. Di Giambendetto, P. Narciso, A. Ammassari, E. Girardi, A. De Luca, and C. F. Perno. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res. Hum. Retrovir. 18:835-838.
2. Bacheler, L., S. Jeffrey, G. Hanna, R. D'Aquila, L. Wallace, K. Logue, B. Cordova, K. Hertogs, B. Larder, R. Buckery, D. Baker, K. Gallagher, H. Scarnati, R. Tritch, and C. Rizzo. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008.
3. Barbour, J. D., F. M. Hecht, T. Wrin, T. J. Liegler, C. A. Ramstead, M. P. Busch, M. R. Segal, C. J. Petropoulos, and R. M. Grant. 2004. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18:1683-1689.
4. Bonneau, P., P. A. Robinson, J. Duan, L. Doyon, B. Simoneau, C. Yoakim, M. Bos, M. Cordingley, B. Brenner, B. Spira, M. Wainberg, F. Huang, K. Drda, C. Ballow, M. Koenen-Bergmann, and D. L. Mayers. 2005. Antiviral characterization and human experience with BILR 355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti-HIV-1 profile, abstr. 558. Abstr. 12th Conf. Retrovir. Opportunistic Infect.
5. Boone, L. R. 2006. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Opin. Investig. Drugs 7:128-135.
6. Broom, C. 1990. Design of first-administration studies in healthy man, p. 206-213. In J. O'Grady and O. I. Linet (ed.), Early phase drug evaluation in man. Macmillan Press, London, United Kingdom.
7. Chen, M., L. Ma, G. L. Drusano, J. S. Bertino, Jr., and A. N. Nafziger. 2006. Sex differences in CYP3A activity using intravenous and oral midazolam 1. Clin. Pharmacol. Ther. 80:531-538.
8. Clotet, B. 2004. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev. 6:123-130.
9. Cvetkovic, R. S., and K. L. Goa. 2003. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63:769-802.
10. Decker, C. J., L. M. Laitinen, G. W. Bridson, S. A. Raybuck, R. D. Tung, and P. R. Chaturvedi. 1998. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci. 87:803-807.
11. de Mendoza, C., C. Rodriguez, J. Colomina, C. Tuset, F. Garcia, J. M. Eiros, A. Corral, P. Leiva, J. Aguero, J. Torre-Cisneros, J. Pedreira, I. Viciana, J. del Romero, A. Saez, R. Ortiz de Lejarazu, and V. Soriano. 2005. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin. Infect. Dis. 41:1350-1354.
12. de Vries-Sluijs, T. E., J. P. Dieleman, D. Arts, A. D. Huitema, J. H. Beijnen, M. Schutten, and M. E. van der Ende. 2003. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin. Pharmacokinet. 42:599-605.
13. Eagling, V. A., D. J. Back, and M. G. Barry. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:190-194.
14. Hogg, R. S., K. V. Heath, B. Yip, K. J. Craib, M. V. O'Shaughnessy, M. T. Schechter, and J. S. Montaner. 1998. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279:450-454.
15. Kilby, J. M., G. Sfakianos, N. Gizzi, P. Siemon-Hryczyk, E. Ehrensing, C. Oo, N. Buss, and M. S. Saag. 2000. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob. Agents Chemother. 44:2672-2678.
16. King, J. R., H. Wynn, R. Brundage, and E. P. Acosta. 2004. Pharmacokinetic enhancement of protease inhibitor therapy. Clin. Pharmacokinet. 43:291-310.
17. Koudriakova, T., E. Iatsimirskaia, I. Utkin, E. Gangl, P. Vouros, E. Storozhuk, D. Orza, J. Marinina, and N. Gerber. 1998. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26:552-561.
18. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
19. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
20. van Heeswijk, R. P., A. Veldkamp, J. W. Mulder, P. L. Meenhorst, J. M. Lange, J. H. Beijnen, and R. M. Hoetelmans. 2001. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir. Ther. 6:201-229.
21. Veldkamp, A. I., G. J. Weverling, J. M. Lange, J. S. Montaner, P. Reiss, D. A. Cooper, S. Vella, D. Hall, J. H. Beijnen, and R. M. Hoetelmans. 2001. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15:1089-1095.
22. Yoakim, C., P. R. Bonneau, R. Deziel, L. Doyon, J. Duan, I. Guse, S. Landry, E. Malenfant, J. Naud, W. W. Ogilvie, J. A. O'Meara, R. Plante, B. Simoneau, B. Thavonekham, M. Bos, and M. G. Cordingley. 2004. Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives. Bioorg. Med. Chem. Lett. 14:739-742.